Amol and Reena want you to understand the following:

1. When added to moderate dose statin, the IMPROVE-IT randomized trial showed that ezetimibe improved clinical outcomes in patients after acute coronary syndrome.

2. A network meta-analysis showed that no blood pressure lowering therapy improved mortality in patients with diabetes and chronic kidney disease. The combination of ACE-inhibitors and angiotensin receptor blockers was the most effective in preventing end-stage kidney disease.

The papers

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62459-4/abstract

Good Stuff

http://www.bmj.com/content/350/bmj.h2942

http://www.slate.com/blogs/the_eye/2015/05/06/empathy_cards_by_emily_mcdowell_are_greeting_cards_designed_for_cancer_patients.html